Randomized controlled trialHumanClinical Trial, Phase III
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
The New England journal of medicine, 2021 Aug 5. Frías JP, Davies MJ, Rosenstock J and 7 others.
Study type
Randomized controlled trial · Clinical Trial, Phase III
Subjects
Human participants (PubMed MeSH: Humans)
Journal
The New England journal of medicine
Published
2021 Aug 5
PubMed
Where PepCue cites this
This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.
Indexed under
MeSH terms assigned by the National Library of Medicine.
Blood GlucoseDiabetes Mellitus, Type 2Dose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationFemaleGastric Inhibitory PolypeptideGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsIncretins
Other papers on Tirzepatide
Randomized controlled trial · 2024
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity
Randomized controlled trial · 2022Tirzepatide Once Weekly for the Treatment of Obesity
PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.
Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page